Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider John Paolini Sells 77,587 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) insider John Paolini sold 77,587 shares of the business’s stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $93.02, for a total transaction of $7,217,142.74. Following the sale, the insider directly owned 69,922 shares of the company’s stock, valued at approximately $6,504,144.44. This trade represents a 52.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ KNSA opened at $93.29 on Wednesday. The company’s 50 day simple moving average is $79.67 and its 200 day simple moving average is $60.56. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $37.02 and a fifty-two week high of $98.48. The firm has a market capitalization of $7.28 billion, a P/E ratio of 71.76 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The firm had revenue of $285.97 million for the quarter, compared to analysts’ expectations of $260.66 million. Sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.30 EPS for the current fiscal year.

Key Kiniksa Pharmaceuticals International News

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Negative Sentiment: Across October 30 and November 2, CAO Michael Megna, COO Ross Moat, CFO Mark Ragosa and insider John Paolini reported sales totaling about 272,600 shares, worth approximately $25.4 million. The selling could weigh on sentiment or temper the stock’s recent momentum. However, each transaction was made under a pre-arranged Rule 10b5-1 plan, so it is not necessarily a response to new company developments. Megna SEC filing Moat SEC filing Paolini SEC filing Ragosa SEC filing

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several large investors have recently bought and sold shares of the company. Allworth Financial LP raised its holdings in Kiniksa Pharmaceuticals International by 42.0% in the second quarter. Allworth Financial LP now owns 453 shares of the company’s stock worth $29,000 after purchasing an additional 134 shares during the period. Arizona State Retirement System boosted its position in shares of Kiniksa Pharmaceuticals International by 2.1% during the second quarter. Arizona State Retirement System now owns 10,132 shares of the company’s stock worth $648,000 after purchasing an additional 209 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 21.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,278 shares of the company’s stock valued at $95,000 after buying an additional 223 shares during the period. Commonwealth Equity Services LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 2.2% in the 3rd quarter. Commonwealth Equity Services LLC now owns 10,871 shares of the company’s stock valued at $811,000 after buying an additional 237 shares during the period. Finally, First Trust Advisors LP grew its holdings in shares of Kiniksa Pharmaceuticals International by 3.1% in the 1st quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock valued at $476,000 after buying an additional 293 shares during the period. Institutional investors own 53.95% of the company’s stock.

Analyst Ratings Changes

KNSA has been the topic of several recent research reports. Wedbush raised their price target on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 28th. The Goldman Sachs Group upped their price objective on Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a report on Wednesday, October 28th. Citigroup increased their target price on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Wells Fargo & Company raised their target price on Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, October 28th. Finally, Canaccord Genuity Group boosted their target price on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $100.57.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.